9 research outputs found

    Kaplan–Meier survival curves for patients with interstitial lung disease associated with primary Sjögren’s syndrome.

    No full text
    <p>(a) Survival curve for the total patient population. Five-year survival rate was 87.3%. (b) Comparison of survival curves between the NSIP (n = 22) and UIP (n = 11) patients. Open circles or open squares show censored cases in NSIP group or UIP group, respectively. The prognosis between the two groups was not significantly different (<i>P</i> = 0.93 in log–rank test). UIP: usual interstitial pneumonia; NSIP: nonspecific interstitial pneumonia.</p

    Examples of pathological scoring (hematoxylin–eosin, × 100).

    No full text
    <p>Typical images in each grade of fibroblastic foci (straight arrows) [(a): grade 1 and (b): grade 3] and bronchiolar fibrosis [(c): grade 1 and (d): grade 3] were listed.</p

    Kaplan-Meier survival curves of all-cause mortality.

    No full text
    <p>Overall cumulative 5-year mortality was 24.4%. (A) Patients with ScAb-ILD (dotted line) had worse survival than those with SSc-ILD (dashed line) (p = 0.011). (B) In patients with ScAb-ILD, those with extensive disease (dashed line) had worse survival than those with limited disease (solid line) (p = 0.015). (C) In patients with SSc-ILD, those with KL-6 ≥ 1000 U/mL (dashed line) had worse survival than those with KL-6 < 1000 U/mL (solid line) (p = 0.049). (D) The survival curves for patients with each type of autoantibody were not significantly different (p = 0.905 for comparison between anti-scleroderma-70 and anti-U1 RNP antibody, p = 0.089 for comparison between anti-scleroderma-70 and anti-centromere antibody, and p = 0.137 for comparison between anti-U1 RNP and anti-centromere antibody).</p

    Changes in forced vital capacity (FVC) during follow-up.

    No full text
    <p>(A) SSc-ILD (B) ScAb-ILD (C) Regression lines were calculated by solving the linear mixed-effects model. Baseline FVC (intercept) with ScAb-ILD (mean, 2.574 L [95% CI: 2.313–2.835]) was significantly higher than that with SSc-ILD (mean, 2.191 L [95% CI: 1.974–2.407]) (p = 0.027). The declining slopes of FVC between both groups were not significantly different (SSc-ILD: mean, -0.03979 L year<sup>-1</sup> [95% CI: -0.05449 to -0.02509]; ScAb-ILD: mean, -0.03740 L year<sup>-1</sup> [95% CI: -0.06446 to -0.01034] (p = 0.878).</p

    HRCT scans of cyst formation.

    No full text
    <p>(A-B) HRCT scan demonstrates cyst formation (arrowheads) with pulmonary fibrosis, traction bronchiectasis, and architectural distortion in two patients with SSc-ILD. There is no continuity between the cysts and traction bronchiectasis. (C) HRCT scan shows cysts (arrowheads) with opacity separated from the pleura in a patient with MCTD-ILD.</p

    Examples of pathological scoring.

    No full text
    <p>(A-B) Typical imaging in each grade of organizing pneumonia (intra-alveolar polyps) as found in patients with ScAb-ILD (hematoxylin-eosin stain) ([A]: grade 1 and [B]: grade 3). (C-D) Vascular intimal or medial thickening as found in patients SSc-ILD (Elastica van Gieson stain) ([C]: grade 1 and [D] grade 3].</p
    corecore